title: Response to "toward personalized sexual medicine: where is the evidence?".
authors: Emotional Brain B.V., Almere, The Netherlands; Utrecht Institute for Pharmaceutical Sciences, Rudolf Magnus Institute of Neuroscience, Utrecht University, Utrecht, The Netherlands.
authors: Adriaan
authors: A
authors: Tuiten
authors: Jos
authors: J
authors: Bloemers
authors: Kim
authors: K
authors: van Rooij
authors: Saskia
authors: S
authors: Poels
authors: Jeroen
authors: J
authors: Gerritsen
authors: Diana
authors: D
authors: van Ham
authors: Leo
authors: L
authors: de Leede
authors: Walter
authors: W
authors: Everaerd
mesh_terms: D000728:Androgens / Q000627:therapeutic use*; D000818:Animals; D002065:Buspirone / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D058825:Serotonin 5-HT1 Receptor Agonists / Q000627:therapeutic use*; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy*; D013450:Sulfones / Q000627:therapeutic use*; D013739:Testosterone / Q000627:therapeutic use*
chemical_list: D000728:Androgens; D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D058825:Serotonin 5-HT1 Receptor Agonists; D013450:Sulfones; D013739:Testosterone; D002065:Buspirone